Molecular imaging has emerged as a transformative paradigm in drug development, enabling the non-invasive visualization of biological processes at the molecular and cellular level through radiolabeled tracers, advanced scanner technologies, and quantitative image analysis. As a specialized Radiopharmaceutical CRDMO and CRO, Protheragen delivers end-to-end Molecular Imaging CRO Services that bridge the gap between preclinical discovery and clinical validation, offering investigators and sponsors the radiochemistry expertise, imaging infrastructure, and regulatory guidance necessary to accelerate the development of novel radiopharmaceuticals and theranostic agents.
Molecular imaging represents a cornerstone of modern radiopharmaceutical development, providing a non-invasive window into the biological and pharmacological behavior of radiolabeled compounds in living organisms. Unlike conventional anatomical imaging modalities such as CT or MRI, which primarily visualize structural morphology, molecular imaging techniques—including PET and SPECT—detect and quantify the distribution of radiotracers that bind to specific molecular targets, metabolic pathways, or cellular processes. This capability is particularly critical in oncology, neurology, and cardiology, where understanding target engagement, receptor occupancy, and tissue-specific uptake is essential for optimizing therapeutic efficacy and minimizing off-target toxicity. In the context of radiopharmaceutical development, molecular imaging serves dual roles: as a diagnostic tool for patient stratification and disease monitoring, and as a therapeutic modality when combined with alpha- or beta-emitting radionuclides in the theranostic paradigm.
Fig 1. Radiolabeling of functional oligonucleotides and its molecular imaging applications. (Liu, Dunfang, et al., 2022)
The selection between PET and SPECT imaging modalities is a pivotal decision in radiopharmaceutical trial design, influencing image quality, quantitative accuracy, logistical feasibility, and overall study cost. While both techniques utilize radiolabeled pharmaceuticals to visualize molecular and cellular processes in vivo, they differ fundamentally in detection physics, spatial resolution, sensitivity, and isotope availability. The table below provides a structured comparison of key technical and operational parameters to guide informed modality selection in molecular imaging CRO services.
| Parameter | PET Imaging | SPECT Imaging |
|---|---|---|
| Spatial Resolution | Clinical devices: 2–6 mm; superior for detecting small lesions and quantifying tracer uptake in discrete tissue volumes. | Clinical devices: 7–15 mm; adequate for organ-level assessment but limited for small-target quantification. |
| Sensitivity & Quantification | Excellent quantitative ability; intrinsic quantification of radiopharmaceutical concentration enables accurate pharmacokinetic modeling, SUV analysis, and dosimetry calculations. | Usually lower quantitative ability compared to PET; attenuation correction and scatter correction are more challenging, limiting absolute quantification accuracy. |
| Multi-Tracer Capability | Only a single radiotracer can be applied per scan session due to overlapping positron energy spectra; sequential scans required for multi-target assessment. | Several radiotracers can be applied simultaneously (multi-tracer imaging) using energy-differentiated acquisition; useful for comparative biodistribution studies. |
| Acquisition Time & Dynamic Imaging | Short acquisition time; dynamic imaging and kinetic modeling are efficient, enabling time-activity curve generation for dosimetry and receptor binding analysis. | Long acquisition time; dynamic imaging and kinetic modeling are impractical for most clinical applications due to lower sensitivity and longer frame requirements. |
| Isotope Production & Availability | Cyclotron production of commonly used radioisotopes (¹⁸F, ¹¹C, ¹⁵O, ¹³N); generator-produced ⁶⁸Ga and ⁶⁴Cu are increasingly available but limited by regional distribution networks. | Generator production of the most commonly used radioisotope (⁹⁹ᵐTc) makes SPECT widely available globally; lower cost per dose and longer shelf-life simplify logistics. |
| Radiation Exposure | Lower radiation dose per unit diagnostic information due to high sensitivity; microdose Phase 0 studies feasible with minimal biological effect. | Generally higher radiation exposure per diagnostic unit; however, specific applications (e.g., ⁹⁹ᵐTc-MDP bone scan) may result in lower exposure than equivalent PET protocols. |
| Primary Clinical Applications | Oncology (FDG, PSMA, DOTA-peptides), neurology (amyloid, tau tracers), cardiology (perfusion, viability), and theranostic dosimetry (⁶⁸Ga/¹⁷⁷Lu pairs). | Cardiac perfusion imaging (⁹⁹ᵐTc-sestamibi), bone metastasis detection (⁹⁹ᵐTc-MDP), thyroid imaging (¹²³I/¹³¹I), and sentinel lymph node mapping. |
| Cost & Accessibility | Higher capital and operational costs; cyclotron dependency limits site availability; preferred for trials requiring high-resolution quantitative endpoints. | Lower cost and broader accessibility; ideal for large-scale screening trials, multi-center studies in resource-limited settings, and applications where quantitative precision is secondary. |
With a full set of world-class pre-clinical research facilities and appropriate qualifications, as well as a sound IIT cooperation network, Protheragen can provide one-stop professional services from radiochemistry, pre-clinical research to IIT human research. Not only can we provide efficient solutions for the development of innovative radiopharmaceuticals, but we can also provide molecular imaging and companion diagnostic drug development services for XDC drugs.
We offer full-cycle PET/CT trial support covering radiolabeling, imaging protocol drafting, scanner calibration and coordinated patient scheduling. We perform static/dynamic scan acquisition, neutral-platform reconstruction and quantitative SUV, TAC and lesion dosimetry analysis, with all data stored in validated EDC systems meeting ALCOA+ standards.
We deliver customized SPECT/CT trial solutions for multiple radionuclide tracers, optimizing attenuation and scatter correction for accurate quantification. We handle radiopharmacy QC and supply logistics, provide ROI analysis, and run tailored post-treatment SPECT scans for alpha-emitting agents to enable personalized patient dosimetry.
Molecular imaging technology provides animals and human bodies with functional information of tissues and organs at the molecular level, shows microscopic activities such as cellular metabolism and signaling, and accurately locates the target tissues and organs, presenting fine anatomical structures, which are widely applied in the fields of oncology, cardiovascular, brain neurology research, and related drug development.
At present, Protheragen has the capability to independently produce diagnostic imaging nuclides such as Cu-64, Ga-68, Zr-89 and F-18. These nuclides can be used to mark small molecules, peptides, antibodies, and various engineered antibodies, such as nanoantibodies and antibody fragments. Protheragen is actively engaged in XDC marking process and quality control research, as well as in vitro cellular testing of marked drugs and in vivo, dynamic, continuous and different time-point imaging and biodistribution studies in small and large animals. These initiatives provide a solid foundation for validating the drug's durability, and significantly accelerate the development schedule while effectively reducing development costs.
Protheragen combines deep radiopharmaceutical expertise with integrated CRDMO and CRO capabilities to deliver Molecular Imaging Services that meet the highest standards of scientific precision, regulatory compliance, and operational reliability. Our multidisciplinary teams understand the unique complexities of molecular imaging—from tracer chemistry and isotope logistics to quantitative image analysis and dosimetry—enabling seamless support for programs at every stage of development.
Whether you are developing a novel PET tracer for oncology imaging, validating a SPECT-based theranostic pair, or seeking a strategic partner to manage your molecular imaging clinical trial, Protheragen is ready to support your program with the scientific expertise, imaging infrastructure, and regulatory guidance it deserves. Reach out to us today to discuss how our Molecular Imaging CRO Services can accelerate your radiopharmaceutical development from preclinical concept to clinical validation. Contact our imaging strategy team to schedule a consultation and explore a tailored partnership approach.
Reference